Latest news

• Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland

  Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland. ... Alecensa is challenging Pfizer’s existing ALK+ lung cancer treatment, Xalkori, alongside another challenger, Novartis’Zycadia.

• Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

  Strong launches for new medicines Ocrevus, Tecentriq and Alecensa, especially in Germany, partially offset the loss in Europe.

• Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

  Xalkori is for now keeping one step ahead of rival treatments, such as Novartis’Zykadia, which gained NICE approval for use in ALK+ patients in January, and Roche’s Alecensa, which

• MSD launches EU’s first biosimilar Herceptin in UK

  has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).

• Pfizer files third-gen ALK inhibitor for lung cancer

  of competitive pressure from Roche’s fast-growing rival Alecensa (alectinib), a second-generation inhibitor that is well-tolerated and has the added benefit of penetrating the brain, which can help ... Alecensa saw sales double to reach around $385m in